北京大学学报(医学版) ›› 2016, Vol. 48 ›› Issue (1): 5-9. doi: 10.3969/j.issn.1671-167X.2016.01.002

• 工作综述 • 上一篇    下一篇

MicroRNA表达与舌鳞癌患者预后的关系及其调控舌鳞癌生物学行为的机制

贾凌飞1,2,甘业华2△,俞光岩1△   

  1. (北京大学口腔医学院·口腔医院 1.口腔颌面外科, 2.中心实验室, 北京100081)
  • 出版日期:2016-02-18 发布日期:2016-02-18
  • 通讯作者: 甘业华,俞光岩 E-mail:gyyu@263.net, kqyehuagan@bjmu.edu.cn

Relationships between microRNA expressions and prognosis in patients with tongue squamous cell carcinoma and the mechanisms microRNA regulating tongue squamous cell carcinoma biological behavior

JIA Ling-fei1, 2, GAN Ye-hua2△, YU Guang-yan1△   

  1. (1. Department of Oral and Maxillofacial Surgery, 2. Central Laboratory, Peking University School and Hospital of Stomatology, Beijing 100081, China)
  • Online:2016-02-18 Published:2016-02-18
  • Contact: GAN Ye-hua, YU Guang-yan E-mail:gyyu@263.net, kqyehuagan@bjmu.edu.cn

摘要:

舌鳞状细胞癌(tongue squamous cell carcinoma,TSCC)简称舌鳞癌,是口腔颌面部最常见的恶性肿瘤之一,恶性程度高,侵袭性强,易发生颈淋巴结转移[1]。MicroRNA(miRNA)对多种恶性肿瘤的生物学行为起重要的调控作用[2-3]。近年来,本课题组对部分抑癌相关miRNA,如miR-195/34a/26a/375/29b与舌鳞癌患者预后的关系以及调控舌鳞癌细胞增殖、周期、迁移、侵袭等生物学行为的分子机制进行了研究,现将其主要结果及意义作一综述。
1miRNA异常表达与舌鳞癌临床病理特征及患者预后的关系
肿瘤的原发部位、大小、病理分级、临床分期等因素均可对患者预后产生影响,对有较高复发率和淋巴结转移倾向的舌鳞癌进行早期预测,并制定有效的治疗计划是提高舌鳞癌患者生存率和生存质量的关键。临床常用的TNM分期不能完整体现肿瘤的遗传学和生物学特征,深入研究与肿瘤发生、发展相关的分子机制以及肿瘤标记物,将有助于提高该肿瘤早期诊断的准确率,制定个性化的辅助治疗方案,更有效地判断患者的预后。
miRNA是一种内源性的非蛋白编码RNA,长度22 nt左右,与靶基因mRNA结合后可以抑制其蛋白质翻译或使mRNA降解,进而调控靶基因的表达,在细胞的多种生命活动,如增殖、分化、生长、新陈代谢、凋亡及肿瘤的发生、发展中起重要作用[4]。多项研究表明舌鳞癌患者肿瘤组织中存在miRNA异常表达谱,提示miRNA有望成为新的肿瘤标志物。

关键词: 舌肿瘤, 癌, 鳞状细胞, 微RNAs, 预后, 肿瘤生物学行为

Abstract:

Tongue squamous cell carcinoma (TSCC) is the most common type of oral cancer and is well known for its high rate of proliferation and lymph nodal metastasis. Exploring the underlying pathways regulating TSCC could provide novel ideas for diagnosis and prognosis of TSCC patients, as well as molecular targets for treatment of TSCC. MicroRNAs (miRNAs) are small noncoding RNAs that inhibit gene expression through the 3′ untranslated regions (3′UTRs) of their target messenger RNAs. They play crucial roles in numerous biological processes, including cancer progression. Although great efforts have been made, what role miRNAs may play in the early detection and diagnosis of TSCC is not fully understood. Recently, our team has performed a series of basic and clinical researches in an attempt to investigate the relationships between miRNA expressions and prognosis of patients with TSCC and the mechanisms under regulation of TSCC. The results showed that miR-195, miR-34a, miR-29b, miR-375 and miR-26a could inhibit TSCC cells progression and development via a sophisticated network of genes. Specifically, the anti-tumor effects of miR-195 in TSCC may be partially mediated by its inhibition of CyclinD1 and Bcl-2 expression. The expression of miR-34a could inhibit migration and invasion of TSCC cell lines via targeting MMP9 and MMP14. The function of miR-29b may be through the miR-29b/Sp1/PTEN/AKT axis. Overexpression of miR-375 inhibited Sp1 expression by targeting the 3′ untranslated region of the Sp1 transcript. MEG3 and miR-26a inhibited TSCC cell proliferation, cycle progression and promoted cell apoptosis and miR-26a could increase the MEG3 expression through reduction of the expression of DNMT3B in TSCC. In light of the role of those miRNAs in diagnosis and prognosis of TSCC, we reported that decreased miR-195 and miR-375 expression was associated with poor overall survival rate of the TSCC patients, while miR-34a expression was negatively correlated with cervical lymph node metastases. Furthermore, combined low expression levels of miR-26a and MEG3 emerged as an independent prognostic factor for poor clinical outcomes in TSCC patients, suggesting that combined miR26a and MEG3 expression might prove useful as an independent biomarker of clinical prognosis among TSCC patients.

Key words: Tongue neoplasms, Carcinoma, squamous cell, MicroRNAs, Prognosis, Biological beha-vior of tumor

中图分类号: 

  • R739.86
[1] 步召德, 冯梦宇, 季科. 早期胃癌行前哨淋巴结导航手术的实践与思考[J]. 北京大学学报(医学版), 2026, 58(2): 239-243.
[2] 王海, 江一舟. 靶向血管治疗在乳腺癌精准治疗中的分子机制与临床应用[J]. 北京大学学报(医学版), 2026, 58(2): 251-256.
[3] 罗必显, 刘洪铭, 谢伟勋, 龚渭华. 产甲胎蛋白胃癌的新临床特征和前沿科学问题[J]. 北京大学学报(医学版), 2026, 58(2): 257-265.
[4] 付浩, 申潞艳, 黄冰洋, 马少华. 免疫治疗背景下食管鳞状细胞癌围手术期治疗的临床思考[J]. 北京大学学报(医学版), 2026, 58(2): 266-271.
[5] 殷昊明, 王子杰, 舒帆, 张展奕, 梁会, 张树栋. 肾透明细胞癌FABP6基因长转录本的表达及意义[J]. 北京大学学报(医学版), 2026, 58(2): 393-398.
[6] 李嘉临, 陈力侨, 唐家天, 吴艳, 王安强. 胃肝样腺癌转化治疗1例[J]. 北京大学学报(医学版), 2026, 58(2): 399-404.
[7] 郭芷均, 俎明, 马超, 张贺军, 张静, 丁士刚. 同时性多发早期胃癌漏诊病灶的临床病理特征[J]. 北京大学学报(医学版), 2026, 58(2): 410-415.
[8] 潘子晨, 陈凯, 侯钰坤, 杨博涵, 张继新, 马永蔌, 田孝东, 杨尹默. 胰腺腺鳞癌临床病理特征与分子机制研究进展[J]. 北京大学学报(医学版), 2026, 58(2): 431-435.
[9] 张铃福, 陈明, 赵小宇, 王港, 崔龙, 凌晓锋, 王立新, 徐智, 郭丽梅, 侯纯升. 原发灶局限于胆囊壁内胆囊癌大体分型及其与预后和癌前病变的相关性[J]. 北京大学学报(医学版), 2026, 58(1): 184-189.
[10] 高雅静, 李正芳, 马梦思, 武丽君. SII和SIRI对白塞病葡萄膜炎的风险预测及疾病活动度和预后的评估[J]. 北京大学学报(医学版), 2025, 57(6): 1067-1073.
[11] 王晓林, 李璐瑶, 张雯, 王鸿雁. 3例子宫体中肾样腺癌的临床病理学分析[J]. 北京大学学报(医学版), 2025, 57(6): 1208-1212.
[12] 侯卫华, 宋书杰, 石中月, 刘露, 金木兰. 食管胃结合部具有显著空泡状核特征的神经内分泌癌1例[J]. 北京大学学报(医学版), 2025, 57(5): 1005-1009.
[13] 谢尚, 王鹿鸣, 张馨元, 冯秋实, 夏洋洋, 戴姿薇, 单小峰, 蔡志刚. 口腔鳞癌类器官库的构建及应用[J]. 北京大学学报(医学版), 2025, 57(5): 847-851.
[14] 李浙民, 季加孚, 李国新, 李子禹, 步召德, 高翔宇, 董迪, 唐磊, 邢晓芳, 贾淑芹, 郭婷, 张连海, 陕飞, 季鑫, 王安强. 胃癌精准诊疗技术的创建与推广[J]. 北京大学学报(医学版), 2025, 57(5): 864-867.
[15] 唐少海, 杨宝明, 李建坤, 赵丽丽, 王仪凡, 王顺祥. HDAC2介导H3K27ac修饰促进肝癌细胞的增殖和迁移[J]. 北京大学学报(医学版), 2025, 57(5): 884-894.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!